Trial Profile
Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma:A Phase I/II Investigator-Initiated Clinical Trial
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mepacrine (Primary) ; Capecitabine
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions
- 24 Mar 2021 Status changed from active, no longer recruiting to discontinued.(the study was stopped due toThe single Quinacrine manufacture facility in the US was shut down by the FDA ).
- 06 May 2020 Planned End Date changed from 1 Jun 2020 to 1 Apr 2021.
- 06 May 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.